02179 RECBIO-B
- 9.150
- +0.160+1.78%
RECBIO-B News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Ricoh Bio-B (02179.HK) elects Liu Yong as chairman
Ruike Bio-B (02179.HK) announced that at the annual shareholders' meeting, Dr. Liu Yong, Mr. Li Bu, Ms. Chen Qingqing and Dr. Hong Kunxue were appointed as executive directors of the 2nd board of directors; Dr. Wang Ruwei, Dr. Zhang Jiaxin, Dr. Zhou Hongbin and Mr. Hu Houwei were appointed as non-executive directors of the 2nd board of directors; and Dr. Xia Lijun, Mr. Liang Guodong, Professor GAO Feng and Professor Yuan Huiming were appointed as independent non-executive directors of the 2nd board of directors.
Ricoh Bio-B (02179) elects Liu Yong as chairman
Recco Bio-B (02179) issued an announcement. At the annual shareholders' meeting, Dr. Liu Yong, Mr. Li Bu, Chen Qingqing...
Recco Bio-B (02179): Qiao Weiwei and Liu Ping were re-elected as employee representative supervisors
Recco Bio-B (02179) issued an announcement. The company held a staff congress on May 7, 2024. Qiao Wei...
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
瑞科生物-B：2023年報
Recco Bio-B (02179) nominated Liu Yong as a candidate for the second board of directors
The term of directors of the second board of directors is three years. It takes effect from the date the relevant bill is reviewed and passed by the company's shareholders' meeting. At the end of their term of office, they can be re-elected.
Recobiotics and Rongsheng Biotech sign a strategic cooperation agreement on a novel adjuvant vaccine project
Taizhou, March 27, 2024/PRNewswire/ -- Recently, Jiangsu Ruike Biotechnology Co., Ltd. (hereinafter referred to as “Recobiology”, stock code: 02179.HK) and Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Rongsheng Biotech”) successfully held a novel adjuvant vaccine R&D project signing and project launch meeting in Shanghai. At the meeting, the two sides signed a strategic cooperation agreement on the novel adjuvant vaccine project and discussed in depth the details of the project progress. Adjuvants are important components in vaccine development, and novel adjuvants have become the key to the success of innovative vaccine development. According to this section of the agreement
Jiangsu Recbio Technology's Loss Narrows in 2023
Jiangsu Recbio Technology's (HKG:2179) attributable loss narrowed to 572 million yuan, or 1.19 yuan per share, in 2023, from 722.7 million yuan, or 1.52 yuan per share, in 2022, according to a Wednesd
Recobiotics Releases 2023 Annual Results Report and Recent Developments
Taizhou, Jiangsu Province, March 21, 2024/PRNewswire/ -- On March 20, innovative vaccine company Recobiology (02179.HK) released its 2023 annual results report and latest developments. Recobiology has always adhered to the vision and mission of “creating first-class vaccines to protect human health”, guided by the company's strategy, and has achieved the following milestones and progress in research and pipeline and business operations. Business Summary REC603-recombinant HPV nine-valent vaccine The recombinant nine-valent HPV vaccine REC603 is undergoing phase III clinical trials in China, and regular follow-up work is being carried out according to the clinical plan.
Recco Bio-B (02179) announced annual results, loss attributable to shareholders of 572 million yuan narrowed 20.86% year over year
Recco Bio-B (02179) announced its annual results for the year ended December 31, 2023. The group...
RECBIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND NO FURTHER EXTENSION OF VALIDITY PERIOD OF RESOLUTIONS ON ISSUANCE OF DOMESTIC SHARES FOR 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Ricoh Bio-B (02179.HK) plans to hold a board meeting on March 20 to consider and approve annual results
Gelonghui, March 8, 丨 Ricoh Bio-B (02179.HK) announced that the board of directors meeting will be held on March 20, 2024 (Wednesday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any).
RECBIO-B: DATE OF BOARD MEETING
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Recco Biologics completes phase I clinical study of the new adjuvant recombinant shingles vaccine in China
Gelonghui, January 30 | Recco Biotech (2179.HK) announced that its self-developed recombinant recombinant herpes zoster vaccine REC610 phase I clinical trial in China has completed the enrollment of the first batch of subjects. Using a randomized, double-blind, parallel-controlled design, the study recruited 180 healthy subjects aged 40 and above in Pu'er City, Yunnan Province to evaluate the safety, tolerability, and immunogenicity of REC610. According to the company's previous news, the product has completed head-to-head clinical studies with GSK Shingrix in the Philippines. The results show that REC610 has cellular immunity and humoral immunity
Analysis
Price Target
No Data
